<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4494912</article-id><article-id pub-id-type="pmid">26059437</article-id><article-categories><subj-group subj-group-type="heading"><subject>Priority Research Paper</subject></subj-group></article-categories><title-group><article-title>Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stoll</surname><given-names>Gautier</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bindea</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mlecnik</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Galon</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zitvogel</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref><xref ref-type="aff" rid="A6"><sup>6</sup></xref><xref ref-type="aff" rid="A7"><sup>7</sup></xref><xref ref-type="aff" rid="A8"><sup>8</sup></xref><xref ref-type="aff" rid="A9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kroemer</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref><xref ref-type="aff" rid="A10"><sup>10</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Universit&#x000e9; Paris Descartes, Sorbonne Paris Cit&#x000e9;, Paris, France</aff><aff id="A2"><sup>2</sup> Equipe 11 labellis&#x000e9;e Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France</aff><aff id="A3"><sup>3</sup> Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, Paris, France</aff><aff id="A4"><sup>4</sup> Universit&#x000e9; Pierre et Marie Curie, Paris, France</aff><aff id="A5"><sup>5</sup> Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France</aff><aff id="A6"><sup>6</sup> Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale, Equipe labellis&#x000e9;e Ligue Nationale Contre le Cancer, Villejuif, France</aff><aff id="A7"><sup>7</sup> Institut Gustave Roussy Cancer Campus, Villejuif, France</aff><aff id="A8"><sup>8</sup> Faculty of Medicine, University of Paris Sud, Kremlin-Bic&#x000ea;tre, France</aff><aff id="A9"><sup>9</sup> Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France</aff><aff id="A10"><sup>10</sup> P&#x000f4;le de Biologie, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, AP-HP, Paris, France</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Guido Kroemer,</italic><email>kroemer@orange.fr</email></corresp></author-notes><pub-date pub-type="collection"><day>20</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>19</day><month>5</month><year>2015</year></pub-date><volume>6</volume><issue>14</issue><fpage>11894</fpage><lpage>11909</lpage><history><date date-type="received"><day>30</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Stoll et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Anticancer immunosurveillance is one of the major endogenous breaks of tumor progression. Here, we analyzed gene expression pattern indicative of the presence of distinct leukocyte subtypes within four cancer types (breast cancer, colorectal carcinoma, melanoma, and non-small cell lung cancer) and 20 different microarray datasets corresponding to a total of 3471 patients. Multiple metagenes reflecting the presence of such immune cell subtypes were highly reproducible across distinct cohorts. Nonetheless, there were sizable differences in the correlation patterns among such immune-relevant metagenes across distinct malignancies. The reproducibility of the correlations among immune-relevant metagenes was highest in breast cancer (followed by colorectal cancer, non-small cell lung cancer and melanoma), reflecting the fact that mammary carcinoma has an intrinsically better prognosis than the three other malignancies. Among breast cancer patients, we found that the expression of a lysosomal enzyme-related metagene centered around <italic>ASAH1</italic> (which codes for N-acylsphingosine amidohydrolase-1, also called acid ceramidase) exhibited a higher correlation with multiple immune-relevant metagenes in patients that responded to neoadjuvant chemotherapy than in non-responders. Altogether, this meta-analysis revealed novel organ-specific features of the immune infiltrate in distinct cancer types, as well as a strategy for defining new prognostic biomarkers.</p></abstract><kwd-group><kwd>meta-analysis of microarrays</kwd><kwd>breast cancer</kwd><kwd>colorectal carcinoma</kwd><kwd>melanoma</kwd><kwd>non-small cell lung cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Ever accumulating preclinical and clinical evidence indicates that anticancer immunosurveillance is (one of) the most important factor(s) that naturally (i.e., in the absence of therapy) limits tumor progression and that determines the efficacy of conventional therapeutic interventions including chemotherapy with cytotoxic drugs and radiotherapy. This general rule applies to most if not all cancers including, but not limited to, breast cancer [<xref rid="R1" ref-type="bibr">1</xref>], colorectal carcinoma [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>], melanoma [<xref rid="R4" ref-type="bibr">4</xref>] and non-small cell lung cancer [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>].</p><p>As a broad principle, it appears that the presence of cytotoxic T lymphocytes, especially if they have a memory effector T cell phenotype [<xref rid="R7" ref-type="bibr">7</xref>-<xref rid="R9" ref-type="bibr">9</xref>], as well as that of conventional dendritic cells, has a positive prognostic impact on cancer patients, in particular if such cells are found within tumor nodules instead of the surrounding stroma [<xref rid="R10" ref-type="bibr">10</xref>]. Moreover, the intratumoral presence of tertiary lymphoid organs, which are elaborate micro-anatomical structures for mounting immune response, has a favorable prognostic value [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R11" ref-type="bibr">11</xref>]. In contrast, a series of other tumor-infiltrating leukocyte subpopulations has a negative impact. This applies to myeloid-derived suppressor cells, macrophages, M2 macrophages, Th2 helper T cells, and regulatory T cells in several major cancer types [<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>]. However, in exceptional cases such as renal cell carcinoma [<xref rid="R14" ref-type="bibr">14</xref>], head and neck cancer [<xref rid="R15" ref-type="bibr">15</xref>] and lymphomas [<xref rid="R10" ref-type="bibr">10</xref>], the infiltration by CD8<sup>+</sup> cytotoxic T lymphocytes may constitute a negative prognostic feature, underscoring different relationships between immunosurveillance and neoplasia in different cancer types.</p><p>There are two major technologies to retrieve information on the immune infiltrate. The first technique consists in performing immunophenotyping of infiltrating leukocytes either in situ (by immunohistochemistry or in situ immunofluorescence staining) or on cell suspensions that are generated by mechanic disruption and enzymatic digestion of fresh tumors. Immunophenotyping yields quantitative information on leukocyte subpopulations (and even information on their spatial distribution, if determined in situ), yet is limited to only a few antigens and is poorly standardized [<xref rid="R10" ref-type="bibr">10</xref>]. The second technique consists in analyzing the presence of distinct mRNA species within the tumor, usually by microarray or RNAseq technology [<xref rid="R16" ref-type="bibr">16</xref>]. This approach, which has the advantage of being highly standardized, yields information on the abundance of different leukocyte subpopulation-specific mRNA species. These results can be &#x02018;deconvoluted&#x02019; by specific techniques, for instance by the analysis of certain groups of genes whose co-regulated expression is characteristic of specific leukocyte subtypes, hence constituting a &#x02018;metagene&#x02019;. More than 30 leukocyte subtypes, each corresponding to a distinct metagene, have been identified in microarray analyses of colon cancers [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R17" ref-type="bibr">17</xref>].</p><p>Recently, we have started the meta-analysis of distinct collections of breast cancer microarrays, observing the existence of immune-relevant metagenes that impact on the therapeutic response to neo-adjuvant chemotherapy [<xref rid="R18" ref-type="bibr">18</xref>], although microarrays data do not provide any direct information on the density of the immune infiltrate. Driven by these encouraging results, we decided to perform a systematic analysis of 20 cohorts representing 4 distinct major cancer types with the scope of comparatively determining the composition of the immune infiltrate, as well as the internal correlations among distinct leukocyte subtype-specific metagenes within each cohort. These analyses revealed that the robustness of the &#x02018;structure&#x02019; of the immune infiltrate varies in different cancer types and that it likely reflects the efficacy of immunosurveillance.</p></sec><sec id="s2"><title>RESULTS AND DISCUSSION</title><sec id="s2_1"><title>Reproducibility of metagenes corresponding to distinct tumor-infiltrating leukocyte subpopulations</title><p>A collection of metagenes that correspond to distinct tumor-infiltrating leukocyte subtypes [<xref rid="R11" ref-type="bibr">11</xref>] was analyzed for their reproducibility across distinct cohorts of cancers. For each cancer type (breast cancer, colorectal carcinoma, melanoma and lung adenocarcinoma), we chose the cohort comprising the largest number of patients to establish leukocyte-specific metagenes in which the relative contribution of each individual gene was weighted (Table <xref ref-type="table" rid="T1">1</xref>). Then, we determined whether this specific metagene could be confirmed in other four cohorts, calculating the <italic>p</italic>-value of reproducibility in each case. While the majority of metagenes were highly reproducible (as this applies for instance for the metagenes indicating the presence of T cells, NK cells, macrophages and neutrophils), a minority was not, including for instance those signifying the presence of regulatory T cells, Tregs, or blood vessels in the tumor, because these metagenes are composed of a single gene (gray squares in Figure <xref ref-type="fig" rid="F1">1</xref>). Metagenes that were considered as reproducible (by visual inspection) are indicated by the blue squares in Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F4">4</xref>, <xref ref-type="fig" rid="F5">5</xref>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of the 20 patient cohorts treated in this meta-analysis</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Cancer type</th><th align="left" valign="middle" rowspan="1" colspan="1">Cohort name</th><th align="left" valign="middle" rowspan="1" colspan="1">Number of samples</th><th align="left" valign="middle" rowspan="1" colspan="1">Characteristics of the cohort</th><th align="left" valign="middle" rowspan="1" colspan="1">Treatment &#x00026; outcome</th><th align="left" valign="middle" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">Xu</td><td align="left" valign="middle" rowspan="1" colspan="1">83</td><td align="left" valign="middle" rowspan="1" colspan="1">Primary and metastatic tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE8401</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">Harlin</td><td align="left" valign="middle" rowspan="1" colspan="1">44</td><td align="left" valign="middle" rowspan="1" colspan="1">Metastatic tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE12627</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">Bogunovic</td><td align="left" valign="middle" rowspan="1" colspan="1">44</td><td align="left" valign="middle" rowspan="1" colspan="1">Metastatic tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE19234</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">RikerMel</td><td align="left" valign="middle" rowspan="1" colspan="1">56</td><td align="left" valign="middle" rowspan="1" colspan="1">Primary and metastatic tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE7553</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">Talantov</td><td align="left" valign="middle" rowspan="1" colspan="1">45</td><td align="left" valign="middle" rowspan="1" colspan="1">Primary tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE3189</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Colon</td><td align="left" valign="middle" rowspan="1" colspan="1">BittColon</td><td align="left" valign="middle" rowspan="1" colspan="1">307</td><td align="left" valign="middle" rowspan="1" colspan="1">Various colon tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE2109</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Colorectal</td><td align="left" valign="middle" rowspan="1" colspan="1">Smith</td><td align="left" valign="middle" rowspan="1" colspan="1">177</td><td align="left" valign="middle" rowspan="1" colspan="1">Various colorectal tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE17536</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Colon</td><td align="left" valign="middle" rowspan="1" colspan="1">Vilar1</td><td align="left" valign="middle" rowspan="1" colspan="1">155</td><td align="left" valign="middle" rowspan="1" colspan="1">Colon tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE26682, 1st set</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Colon</td><td align="left" valign="middle" rowspan="1" colspan="1">Vilar2</td><td align="left" valign="middle" rowspan="1" colspan="1">176</td><td align="left" valign="middle" rowspan="1" colspan="1">Colon tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE26682, 2nd set</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Colon</td><td align="left" valign="middle" rowspan="1" colspan="1">TCGA</td><td align="left" valign="middle" rowspan="1" colspan="1">174</td><td align="left" valign="middle" rowspan="1" colspan="1">Various colon tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">TCGA consortium</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Breast</td><td align="left" valign="middle" rowspan="1" colspan="1">TCGA</td><td align="left" valign="middle" rowspan="1" colspan="1">522</td><td align="left" valign="middle" rowspan="1" colspan="1">Various breast tumors</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">TCGA consortium</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Breast</td><td align="left" valign="middle" rowspan="1" colspan="1">Bonnefoi</td><td align="left" valign="middle" rowspan="1" colspan="1">161</td><td align="left" valign="middle" rowspan="1" colspan="1">Locally advance or large operable breast tumors, estrogen receptor negative</td><td align="left" valign="middle" rowspan="1" colspan="1">FEC or ET treatment. Pathological complete response (complete disappearance of the tumour with no more than a few scattered tumour cells) <italic>vs</italic> no pathological complete response</td><td align="left" valign="middle" rowspan="1" colspan="1">GSE6861</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Breast</td><td align="left" valign="middle" rowspan="1" colspan="1">Hatzis</td><td align="left" valign="middle" rowspan="1" colspan="1">198</td><td align="left" valign="middle" rowspan="1" colspan="1">HER2 negative breast tumors</td><td align="left" valign="middle" rowspan="1" colspan="1">Taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive. Pathological complete response (no invasive or metastatic breast cancer identified) <italic>vs</italic> rapid development</td><td align="left" valign="middle" rowspan="1" colspan="1">GSE25065</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Breast</td><td align="left" valign="middle" rowspan="1" colspan="1">Tabchy</td><td align="left" valign="middle" rowspan="1" colspan="1">178</td><td align="left" valign="middle" rowspan="1" colspan="1">Various type of breast tumors before treatment</td><td align="left" valign="middle" rowspan="1" colspan="1">FEC or FAC neo-adjuvant chemotherapy. Pathological complete response <italic>vs</italic> residual disease (clinical or radiological progression)</td><td align="left" valign="middle" rowspan="1" colspan="1">GSE20271</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Breast</td><td align="left" valign="middle" rowspan="1" colspan="1">Korde</td><td align="left" valign="middle" rowspan="1" colspan="1">61</td><td align="left" valign="middle" rowspan="1" colspan="1">Various type of breast tumors, stage 2 or 3 breast cancer with tumor size &#x02265;2cm at patients selection, prior to AC treatment</td><td align="left" valign="middle" rowspan="1" colspan="1">4 cycles of TX, 4 cycles of adriamycin, cyclophosphamide on day 1 and 21 (neoadjuvant) and AC (neo-adjuvant or adjuvant). Response vs no response (change in tumor size by clinical exam and pathological response).</td><td align="left" valign="middle" rowspan="1" colspan="1">GSE18728</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lung</td><td align="left" valign="middle" rowspan="1" colspan="1">AdenoConsortium</td><td align="left" valign="middle" rowspan="1" colspan="1">462</td><td align="left" valign="middle" rowspan="1" colspan="1">Various type of Adenocarcinomas</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Director's Challenge Lung Study, National Cancer Institute (NHI)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lung</td><td align="left" valign="middle" rowspan="1" colspan="1">Lee</td><td align="left" valign="middle" rowspan="1" colspan="1">138</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenocarcinoma and squamous cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE8894</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lung</td><td align="left" valign="middle" rowspan="1" colspan="1">Okayama</td><td align="left" valign="middle" rowspan="1" colspan="1">226</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenocarcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE31210</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lung</td><td align="left" valign="middle" rowspan="1" colspan="1">Raponi</td><td align="left" valign="middle" rowspan="1" colspan="1">130</td><td align="left" valign="middle" rowspan="1" colspan="1">Squamous cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GSE4573</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lung</td><td align="left" valign="middle" rowspan="1" colspan="1">TCGA</td><td align="left" valign="middle" rowspan="1" colspan="1">134</td><td align="left" valign="middle" rowspan="1" colspan="1">squamous cell carcinoma</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">TCGA consortium</td></tr></tbody></table></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Immune metagene reproducibility</title><p>Heat maps of reproducibility <italic>p</italic>-values, for each cancer type, for each immune metagene, in each dataset. <italic>P</italic>-values are produced by reproducibility test described in Material and Methods (by definition, reproducibility in the learning dataset has a 0 <italic>p</italic>-value). Blue rectangles represent reproducible metagenes. Grey rectangles represent single-gene metagenes (in that case, reproducibility <italic>p</italic>-value always equals to 1).</p></caption><graphic xlink:href="oncotarget-06-11894-g001"/></fig></sec><sec id="s2_2"><title>Correlation of leukocyte subpopulation-associated metagenes in distinct cancer types and cohorts</title><p>In the next step, we determined the Pearson's correlation coefficients (R values) for a matrix comprising all immune-related metagenes for the largest melanoma cohort denoted &#x02018;Xu&#x02019; according to the name of the first author of the paper describing the cohort [<xref rid="R19" ref-type="bibr">19</xref>]. This matrix revealed some strong positive correlations (for instance between CD8 T cells and cytotoxic cells or between T and B cells), which were denoted in red, as well as some negative correlations (for instance between follicular helper T cells [TFH] on one side and B or T cells on the other side), which were denoted in green (Figure <xref ref-type="fig" rid="F2">2A</xref>). The same correlation matrix was re-calculated for four distinct melanoma cohorts denoted &#x02018;Harlin&#x02019;, &#x02018;Bogunovic&#x02019;, &#x02018;RikerMel&#x02019;, &#x02018;Talantov&#x02019; according to the names of the authors describing them [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>]. While some correlations including the aforementioned ones are conserved across the cohorts, other positive and negative correlations appeared to be cohort-specific (Figure <xref ref-type="fig" rid="F2">2B-2E</xref>). We then calculated the reproducibility of the correlations as a <italic>p</italic>-value, meaning that positive or negative correlations, as well as absent correlations, that were observed throughout all cohorts received a low p value, denoted as black or dark grey, while major variations in the correlations received a high p value, denoted as light grey or white (Figure <xref ref-type="fig" rid="F2">2F</xref>). We then applied the same type of meta-analysis to colorectal cancers in which we calculated a first correlation matrix on the &#x02018;Bitt&#x02019; cohort (<ext-link ext-link-type="uri" xlink:href="http://www.intgen.org/">http://www.intgen.org/</ext-link>) (Figure <xref ref-type="fig" rid="F3">3A</xref>), re-calculated this matrix for four additional cohorts (Smith [<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>], Vilar1 &#x00026; Vilar2 [<xref rid="R26" ref-type="bibr">26</xref>-<xref rid="R28" ref-type="bibr">28</xref>], TCGA (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>)) (Figure <xref ref-type="fig" rid="F3">3B-3E</xref>), and determined the reproducibility among such correlations (Figure <xref ref-type="fig" rid="F3">3F</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Immune metagene correlations (A-E) and correlation reproducibility <italic>p</italic>-values (F), in melanoma; reproducible correlations of first dataset (G), identified by hierarchical clustering of reproducibility <italic>p</italic>-values (H)</title><p>Heat map representation of metagene correlation matrices, in the 5 datasets of melanoma transcriptome (blue rectangle corresponds to reproducible metagenes of Figure <xref ref-type="fig" rid="F1">1</xref>). A correlation reproducibility test is applied to the 5 correlation matrices, producing a matrix of p-values. Clustering of correlation reproducibility (H) allows for the identification of a sub-part of correlation matrix (yellow square), represented for the learning dataset (G).</p></caption><graphic xlink:href="oncotarget-06-11894-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Immune metagene correlations (A-E) and correlation reproducibility <italic>p</italic>-values (F), in colorectal cancer; reproducible correlations of first dataset (G), identified by hierarchical clustering of reproducibility <italic>p</italic>-values (H)</title><p>Heatmap representation of metagene correlation matrices, in the 5 datasets of melanoma transcriptome (blue rectangle corresponds to reproducible metagenes of Figure <xref ref-type="fig" rid="F1">1</xref>). A correlation reproducibility test is applied to the 5 correlation matrices, producing a matrix of <italic>p</italic>-values. Clustering of correlation reproducibility (H) allows identifying sub-part of correlation matrix (yellow square), represented for the learning dataset (G).</p></caption><graphic xlink:href="oncotarget-06-11894-g003"/></fig><p>Similarly, we calculated correlation matrices for the &#x02018;TCGA&#x02019; breast cancer cohort (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>) (Figure <xref ref-type="fig" rid="F4">4A</xref>) and four smaller cohorts (Bonnefoi [<xref rid="R29" ref-type="bibr">29</xref>], Hatzis [<xref rid="R30" ref-type="bibr">30</xref>], Tabchy [<xref rid="R31" ref-type="bibr">31</xref>], Korde [<xref rid="R32" ref-type="bibr">32</xref>]) (Figure <xref ref-type="fig" rid="F4">4B-4E</xref>) and the resulting correlation reproducibility (Figure <xref ref-type="fig" rid="F4">4F</xref>). Finally, we determined immune cell subtype-related correlation matrices for the large &#x02018;AdenoConsortium&#x02019; cohort of non-small cell lung cancers [<xref rid="R33" ref-type="bibr">33</xref>] (Figure <xref ref-type="fig" rid="F5">5A</xref>), four additional cohorts (Lee [<xref rid="R34" ref-type="bibr">34</xref>], Okayama [<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>], Raponi [<xref rid="R37" ref-type="bibr">37</xref>], TCGA (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>)) (Figure <xref ref-type="fig" rid="F5">5B-5E</xref>), and their reproducibility (Figure <xref ref-type="fig" rid="F5">5F</xref>). These correlation matrices were then subjected to a meta-analysis to reveal organ-specific differences in the characteristics of the immune infiltrate that can be deduced from microarray data.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Immune metagene correlations (A-E) and correlation reproducibility <italic>p</italic>-values (F), in breast cancer; reproducible correlations of first dataset (G), identified by hierarchical clustering of reproducibility <italic>p</italic>-values (H)</title><p>Heatmap representation of metagene correlation matrices, in the 5 datasets of melanoma transcriptome (blue rectangle corresponds to reproducible metagenes of Figure <xref ref-type="fig" rid="F1">1</xref>). A correlation reproducibility test is applied to the 5 correlation matrices, producing a matrix of <italic>p</italic>-values. Clustering of correlation reproducibility (H) allows identifying sub-part of correlation matrix (yellow square), represented for the learning dataset (G).</p></caption><graphic xlink:href="oncotarget-06-11894-g004"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Immune metagene correlations (A-E) and correlation reproducibility <italic>p</italic>-values (F), in lung cancer; reproducible correlations of first dataset (G), identified by hierarchical clustering of reproducibility <italic>p</italic>-values (H)</title><p>Heatmap representation of metagene correlation matrices, in the 5 datasets of melanoma transcriptome (blue rectangle corresponds to reproducible metagenes of Figure <xref ref-type="fig" rid="F1">1</xref>). A correlation reproducibility test is applied to the 5 correlation matrices. producing a matrix of <italic>p</italic>-values. Clustering of correlation reproducibility (H) allows identifying sub-part of correlation matrix (yellow square), represented for the learning dataset (G).</p></caption><graphic xlink:href="oncotarget-06-11894-g005"/></fig></sec><sec id="s2_3"><title>A meta-analysis of distinct leukocyte and stress response-associated metagenes in distinct cancer types</title><p>For the purpose of the meta-analysis, we included all reproducible correlations, i.e. correlations that received a global p value of &#x0003c;0.1 (note that this threshold was high because there were very few correlations with reproducibility p-values &#x0003c;5%, as indicated in Figure <xref ref-type="fig" rid="F6">6D</xref>) and analyzed their distribution for each cancer type. The density plots shown in Figure <xref ref-type="fig" rid="F6">6A</xref> indicate clear organ-specific differences in the correlations among metagenes reflecting the cancer immune infiltrate. A finer analysis of these correlations can be obtained by separating these densities into two modes, by means of an expectation maximization algorithm (Figure <xref ref-type="fig" rid="F6">6B</xref>). In melanomas and in mammary carcinomas the higher modes of the correlation coefficient (R) were superior to those observed in colorectal cancer and in non-small cell lung cancer (Figure <xref ref-type="fig" rid="F6">6C, 6E</xref>). In mammary carcinoma, the range of correlation coefficients of the lower mode was broader than for the three other cancer types (Figure <xref ref-type="fig" rid="F6">6D, 6E</xref>). As a correlate of this finding, reproducible correlation matrices exhibited more anticorrelated subgroups in breast cancer microarrays (Figure <xref ref-type="fig" rid="F4">4G</xref>) than for all other cancer types (Figures <xref ref-type="fig" rid="F2">2G</xref>, <xref ref-type="fig" rid="F3">3G</xref>, <xref ref-type="fig" rid="F5">5G</xref>). The reproducibility of correlations among immune subtype-related metagenes also revealed organ-specific variations, as indicated by box plot analysis (Figure <xref ref-type="fig" rid="F6">6D</xref>). Thus, the reproducibility of such correlations was the highest (with hence the lowest p values), in breast cancer, followed by colorectal carcinoma, non-small cell lung cancer and melanoma. As a visual correlate of this finding, the black color (which symbolizes high reproducibility) is more preponderant in correlation reproducibility matrices describing breast cancer microarray (Figure <xref ref-type="fig" rid="F4">4F</xref>) than in other cancer types (Figures <xref ref-type="fig" rid="F2">2F</xref>, <xref ref-type="fig" rid="F3">3F</xref>, <xref ref-type="fig" rid="F5">5F</xref>).</p><p>Subsequently we extended this type of analysis beyond the immune system, by looking at metagenes that reflect endoplasmic reticulum (ER) stress, lysosomal function and autophagy, while correlating such metagenes with immune cell subtype-relevant metagents (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1</xref>). Globally, the mean R values obtained for this kind of correlation was close to zero for all cancer types (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1A</xref>). However the reproducibility of correlations was somewhat better for colorectal and mammary carcinomas than for lung cancers and melanomas (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1B</xref>). Nonetheless, there were rather few correlations between, on one hand, immune parameters and, on the other hand, cellular functions (ER stress, lysosomal function, autophagy) that reached statistical significance (<italic>p</italic> &#x0003c; 0.05), much less though than this was found within the immune cell subtype-specific metagenes (Figure <xref ref-type="fig" rid="F6">6D</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1B</xref>).</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Global pattern of reproducible correlations and correlation reproducibility, for immune metagene correlations</title><p><bold>A.</bold> Density plot of reproducible correlations (reproducibility <italic>p</italic>-value &#x0003c;10%) for each cancer type; <bold>B.</bold> Plot of densities, separated in two modes by means of the expectation&#x02013;maximization algorithm; <bold>C.</bold> Box plot representation of the two modes in <bold>B</bold>; <bold>D.</bold> Box plot representation of correlation reproducibility <italic>p</italic>-values; <bold>E.</bold><italic>t</italic>-test <italic>p</italic>-values of reproducible correlations across distinct cancer types, referring to the high modes shown in C; <bold>F.</bold>
<italic>t</italic>-test <italic>p</italic>-values of reproducible correlations, comparing cancer type, referring to the low modes shown in <bold>C</bold>. Boxplots of reproducible correlations used the values of metagene correlations in the learning dataset (in Figures <xref ref-type="fig" rid="F2">2</xref>-<xref ref-type="fig" rid="F4">4</xref>, A, excluding diagonal elements), for which correlation reproducibility had a <italic>p</italic>-value &#x0003c; 10%. Boxplots of correlation reproducibility distribution used matrices of Figures <xref ref-type="fig" rid="F2">2</xref>-<xref ref-type="fig" rid="F5">5</xref>, (excluding diagonal elements).</p></caption><graphic xlink:href="oncotarget-06-11894-g006"/></fig></sec><sec id="s2_4"><title>Prognostic features of individual metagene correlations in breast cancer</title><p>Clinical information on the response of breast cancer patients to neo-adjuvant chemotherapy was available for four out of the five cohorts (Bonnefoi, Hatzis, Tabchy, Korde) analyzed in this study, allowing us to classify patients into &#x02018;responders&#x02019; and &#x02018;non-responders&#x02019; (Table <xref ref-type="table" rid="T1">1</xref>). We previously reported on three of these four cohorts, showing that a high level of expression of a CXCL13-centered, highly reproducible metagene signature indicative of the intratumoral presence of interferon-&#x003b3;-producing T cells had positive prognostic features, as did a number of additional immune-related metagenes [<xref rid="R18" ref-type="bibr">18</xref>]. We used this information to interrogate our databases with regard to the following two questions. First, are their correlations among immune cell type-related metagenes that distinguish responders and non-responders? Second, are there correlation between immune cell type-related metagenes and cell-stress related metagenes that differ among responders and non-responders?</p><p>To respond to these questions, we followed a strategy (Figure <xref ref-type="fig" rid="F7">7A</xref>) that involved the generation of reproducible metagenes with the consequent exclusion of non-reproducible metagenes (as in Figure <xref ref-type="fig" rid="F1">1</xref>), the meta-analysis of correlations among metagenes and the subsequent exclusion of non-reproducible correlations (as in Figure <xref ref-type="fig" rid="F3">3</xref>), followed by the analysis of correlations among metagenes that differ between responders and non-responders, including only those differences that showed some degree of coherence among the four analyzable cohorts (with a combined <italic>p</italic>-value calculated according to Fisher's exact test of <italic>p</italic> &#x0003c; 0.05). Only very few correlations among immune cell type-related metagenes differed among responders and non-responders (Figure <xref ref-type="fig" rid="F7">7B</xref>). Thus the correlation between a metagene reflecting the intratumoral presence of Th2 cells and other leukocyte subtypes (T cells, neutrophils, macrophages, cytotoxic cells, B cells) tended to have higher R values in non-responders (start of the arrows in Figure <xref ref-type="fig" rid="F7">7B</xref>) than in responders (arrowheads in Figure <xref ref-type="fig" rid="F7">7B</xref>), although these trends were not uniform among all four cohorts.</p><p>We identified a few correlations between immune cell type-related metagenes and cell stress-related metagenes that neatly distinguished responders from non-responders (Figure <xref ref-type="fig" rid="F7">7C</xref>). Among these, one metagene (ASAH1) correlated more with a number of leukocyte subtype-related metagenes (T cells, macrophages, immature dendritic cells, neutrophils, B cells) in responders than in non-responders. This trend was uniform among all four cohorts. <italic>ASAH1</italic> codes for N-acylsphingosine amidohydrolase-1 (also called acid ceramidase), the enzyme that catalyzes the synthesis and degradation of ceramide into sphingosine, both of which have immunomodulatory functions [<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>]. <italic>ASAH1</italic> formed a reproducible metagene with a few other lysosome-relevant genes, namely <italic>FUCA1</italic> (which codes for tissue alpha-L-fucosidase, which breaks down fucose), <italic>CLN5</italic> (coding for ceroid-lipofuscinosis neuronal protein 5), <italic>MAN2B2</italic> (which codes for mannosidase, alpha, class 2B, member) and <italic>SMPD1</italic> (coding for sphingomyelin phosphodiesterase 1, also known as acidic sphingomyelinase, ASM) (Figure <xref ref-type="fig" rid="F7">7C</xref>). This was not directly related to metagene expression levels because many leukocyte-related metagenes were overexpressed in responsive tumors, contrasting with the ASAH1 metagene that was actually underexpressed in responsive tumors (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 8</xref>).</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>Variability of metagene correlations, upon treatment response in breast cancer</title><p><bold>A.</bold> Flow chart for producing B &#x00026; C. (B &#x00026; C) Metagene correlations, when they are significantly different upon treatment response, <bold>B.</bold> for immune metagenes, <bold>C.</bold> for correlations between immune metagenes and ER-stress (C.1), lysosome (C.2), autophagy (C.3). Heads of arrow represent correlations for responsive tumors, tails of arrow represent correlation for non-responsive tumors. <italic>P</italic>-values were associated to the combination of correlation difference, as delineated in A. Colors represent different datasets. On the left, details of metagene are plotted, for ER-stress, lysosomes and autophagy (the name of a metagene is defined by its most representative gene).</p></caption><graphic xlink:href="oncotarget-06-11894-g007a"/><graphic xlink:href="oncotarget-06-11894-g007b"/></fig></sec><sec id="s2_5"><title>Concluding remarks</title><p>The present study revealed that multiple metagenes initially designed for the analysis of leukocyte subtypes infiltrating colorectal cancers [<xref rid="R11" ref-type="bibr">11</xref>] were highly reproducible across distinct cancer cohorts, underscoring that they indeed share cell type-specific expression patterns that are stable enough to be detectable in different tissues, including the highly heterogeneous tumor microenvironment. Subsequent correlation analyses demonstrated a large number of positive correlations in the expression of distinct immune-related metagenes. However, there was a neat difference among the four cancer types included in this meta-analysis. For example, the strength of positive correlations was stronger in breast cancer and melanoma then in colon and lung carcinomas. Moreover, breast cancer represented the only type of malignancy in which multiple negative correlations were tangible and reproducible. The reproducibility of the correlations among immune-relevant metagenes was stronger in mammary carcinoma (followed by colorectal cancer, non-small cell lung cancer and melanoma, in this order), reflecting the fact that breast cancer has an intrinsically better prognosis than the three other malignancies [<xref rid="R40" ref-type="bibr">40</xref>]. It is tempting to translate these statistical calculations in immunological terms. Indeed, the strong and homeostatic correlations among the expression patterns of distinct immune cell subtype-specific metagenes suggest that, in breast cancer, immune infiltrates &#x02013; if present &#x02013; are highly organized, contrasting with other cancer types where such an organization, perhaps in tertiary lymphoid structures [<xref rid="R5" ref-type="bibr">5</xref>], may be less efficient, resulting in the presence of isolated (or few) lymphoid and myeloid subpopulations. Systematic histological and immunohistochemical analyses will be required to explore this speculation at the experimental level.</p><p>We were unable to detect highly consistent shifts in the correlation among immune cell subtype-relevant metagenes that would distinguish responders and non-responders among a population of breast cancer patients treated with neo-adjuvant chemotherapy. Obviously, there are large differences in the characteristics of these populations as well as in the treatment schedules (Table <xref ref-type="table" rid="T1">1</xref>) that might render undetectable any subtle impact of such intra-immune correlations on the fate of breast cancer patients. In contrast, we found consistent shifts in the relationship between the expression level of one lysosome-relevant metagene (composed by <italic>ASAH1</italic>, <italic>FUCA1</italic>, <italic>CLN5</italic>, <italic>MAN2B2</italic> and <italic>SMPD1</italic>, which all code for lysosomal hydrolases with the exception of <italic>CLN5</italic>) and several major leukocyte populations (including T and B lymphocytes, as well as several major myeloid cell types, including immature dendritic cells, macrophages and neutrophils) from responders to non-responders [<xref rid="R41" ref-type="bibr">41</xref>]. In responders, these correlations tended to be more positive than in non-responders. High expression of <italic>ASAH1</italic> (independently of any immune parameter) is associated with positive prognosis in breast cancer [<xref rid="R42" ref-type="bibr">42</xref>], and the estrogen receptor antagonist tamoxifen reportedly inhibits this enzyme via an off-target effect [<xref rid="R43" ref-type="bibr">43</xref>]. High expression of <italic>FUCA1</italic> also has been attributed a positive prognostic value in breast cancer [<xref rid="R44" ref-type="bibr">44</xref>]. These results are based on microarray results as well, meaning that there is information available whether these genes are expressed by immune cells or by other parenchymatous and stromal elements of the tumor.</p><p>Irrespective of these uncertainties, the present study reveals novel facets of the correlations between immune- and cell stress-related metagenes. In particular, it appears that the immune system is more &#x02018;structured&#x02019; (with a higher degree of reproducible positive correlations in the expression or leukocyte subtype-related metagenes) in the immune infiltrate of tumors with an intrinsically favorable prognosis such as breast cancer than in cancers with a poor prognosis such as non-small cell lung cancer and melanoma.</p></sec></sec><sec sec-type="materials|methods" id="s3"><title>MATERIALS AND METHODS</title><sec id="s3_1"><title>Datasets</title><p>Public datasets of transcriptome microarray were considered. For each cancer type, 5 transcriptome datasets were used. Among the 5 datasets, the first one (with the largest number of samples) was used as &#x0201c;learning&#x0201d; dataset in order to construct metagenes.</p><p>For Melanoma, the following datasets were used:</p><p>&#x0201c;Xu&#x0201d; for melanomas from dataset GSE8401 (83 samples), &#x0201c;Harlin&#x0201d; for melanomas from dataset GSE12627 (44 samples), &#x0201c;Bogunovic&#x0201d; for melanomas from dataset GSE19234 (44 samples), &#x0201c;RikerMel&#x0201d; for melanomas from skin cancer dataset GSE7553 (56 samples), &#x0201c;Talantov&#x0201d; for melanomas from dataset GSE3189 (45 samples).</p><p>For Colon cancers, the following datasets were used:</p><p>&#x0201c;BittColon&#x0201d; for colon cancers from multi-cancer dataset GSE2109 (307 samples), &#x0201c;Smith&#x0201d; for colorectal cancers of dataset GSE17536 (177 samples), &#x0201c;Vilar1&#x0201d; for colon cancers of the dataset GSE26682 (first part, 155 samples), &#x0201c;Vilar2&#x0201d; for colon cancers of the dataset GSE26682 (second part, 176 samples), &#x0201c;TCGA&#x0201d; for colon cancers from TCGA consortium (174 samples).</p><p>For Breast cancers, the following datasets were used:</p><p>&#x0201c;TCGA&#x0201d; for breast cancers from TCGA consortium (522 samples), &#x0201c;Bonnefoi&#x0201d; for breast cancers from dataset GSE6861 (161 samples), &#x0201c;Hatzis&#x0201d; for breast cancers from dataset GSE25065 (198 samples), &#x0201c;Tabchy&#x0201d; for breast cancers from dataset GSE20271 (178 samples), &#x0201c;Korde&#x0201d; for breast cancers from dataset GSE18728 (61 samples). The latter four datasets were chosen because treatment response are annotated.</p><p>For Lung cancers, the following datasets were used:</p><p>&#x0201c;LungAC&#x0201d; for lung adenocarcinoma from a consortium (Director's Challenge Lung Study, National Cancer Institute (NHI)) (462 samples), &#x0201c;Lee&#x0201d; for lung adenocarcinoma and squamous cell carcinoma of the dataset GSE8894 (138 samples), &#x0201c;Okayama&#x0201d; for lung adenocarcinoma of the dataset GSE31210 (226 samples), &#x0201c;Raponi&#x0201d; for squamous cell carcinoma of the dataset GSE4573 (130 samples), &#x0201c;TCGA&#x0201d; for squamous cell carcinoma from TCGA consortium (134 samples). We joined these two lung cancer subtypes to have enough samples for statistical analysis. It should be noted that the metagene correlation matrices did not exhibit different patterns according to the distinct tumor subtypes (Figure <xref ref-type="fig" rid="F5">5</xref>).</p><p>If transcriptome were produced by Affymetrix&#x000ae; technology (<ext-link ext-link-type="uri" xlink:href="http://www.affymetrix.com">www.affymetrix.com</ext-link>), the best probe sets were chosen according to &#x0201c;Jetset&#x0201d; annotation ([<xref rid="R45" ref-type="bibr">45</xref>]).</p><p>Datasets were downloaded and processed within the R environment [<xref rid="R46" ref-type="bibr">46</xref>].</p><p>For all datasets, normalized data available on the web was used. Log (base 2) was taken for those datasets that did not have Gaussian tails in their expression distribution.</p></sec><sec id="s3_2"><title>Construction of metagenes</title><p>Metagenes were constructed according to the method described in Stoll et al. [<xref rid="R18" ref-type="bibr">18</xref>], by identifying sets of genes and assigning coefficients inside sets:</p><p>1) Identification of sets of genes. For immune metagenes, sets were taken from Bindea et al. [<xref rid="R11" ref-type="bibr">11</xref>], using genes that represent immune cell types. For other metagenes, (autophagy, ER-stress and lysosome), sets of genes were extracted from genes related to autophagy, ER-stress and lysosomes [<xref rid="R18" ref-type="bibr">18</xref>]. Hierarchical clustering was applied to these genes in the learning dataset. Hierarchical clusters were reduced to obtain a maximum of 20 gene sets related to autophagy, ER-stress and lysosomes.</p><p>2) Assignation of gene coefficients. Inside each gene set, coefficients were obtained by performing principal component analyses on covariance of gene expression, keeping the first component, in the learning dataset. By construction, metagenes differed for each cancer type.</p></sec><sec id="s3_3"><title>Correlation of metagenes</title><p>Correlations of metagenes were obtained by calculating Pearson's correlation coefficients applied to metagene expressions. For a given sample, metagene expression was obtained as the scalar product of gene expressions and gene coefficients within the metagene. We construct a submatrix of metagene correlations for each learning dataset (Figures <xref ref-type="fig" rid="F2">2G</xref>-<xref ref-type="fig" rid="F5">5G</xref>). Visual inspection of correlation reproducibility led to the identification of the subpart of the correlation matrix that was most reproducible (yellow rectangle in bottom left of Figures <xref ref-type="fig" rid="F2">2H</xref>-<xref ref-type="fig" rid="F5">5H</xref>).</p><p>Pearson's correlation was chosen because each datasets have Gaussian tails in their expression distribution. Nonetheless, it has been shown [<xref rid="R47" ref-type="bibr">47</xref>] that low expression values in microarrays poorly correlate with expression values obtained by qPCR, which can affect the value of correlation coefficients. To test this, we considered alternative metagene correlations by removing data for genes that are poorly expressed and hence fall into the lower tail of the gene expression distribution. We used non-equality correlation tests (Steiger test in R [<xref rid="R46" ref-type="bibr">46</xref>], package &#x0201c;psych&#x0201d; [<xref rid="R48" ref-type="bibr">48</xref>]), to determine if metagene correlation coefficients depended on such outliers. We applied this procedure to the two largest Affymetrix&#x000ae; datasets in breast carcinoma (Bonnefoi and Hatzis), within immune metagenes. Global correlation patterns (similar to Figure <xref ref-type="fig" rid="F6">6</xref>) were stable (see <xref ref-type="supplementary-material" rid="SD1">Supplemental Figures 2</xref> and <xref ref-type="fig" rid="F3">3</xref>) and almost all <italic>p</italic>-values associated with correlation differences were larger than 5% (see <xref ref-type="supplementary-material" rid="SD1">Supplemental Figures 4</xref> and <xref ref-type="fig" rid="F5">5</xref> for <italic>p</italic>-value distribution)</p><p>The cancer stage dependence was tested by means of a similar procedure. The TCGA dataset was separated into two parts encompassing either stages I-II or stages III-IV. Global correlation patterns are shown in <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 6</xref>, for immune metagene correlation coefficients. The difference between boxplots is smaller than those observed between different cancer types in Figure <xref ref-type="fig" rid="F6">6C</xref>. Most <italic>p</italic>-values associated with correlation difference are larger than 5% (see <xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 7</xref> for <italic>p</italic>-value distribution).</p></sec><sec id="s3_4"><title>Statistical tests</title><p>Metagene reproducibility was computed according to Stoll et al. [<xref rid="R18" ref-type="bibr">18</xref>], using a bootstrapping method that compared metagene components. By construction, a <italic>p</italic>-value was associated with each metagene, in each non-learning dataset.</p><p>Metagene correlation reproducibility was computed according to Stoll et al. [<xref rid="R18" ref-type="bibr">18</xref>], using a bootstrapping method based on correlation variance between datasets. This method is different from a more classical approach that would combine correlation <italic>p</italic>-values; in particular, low values of correlation that are similar within datasets produce a low <italic>p</italic>-value of correlation reproducibility. In addition, this bootstrapping approach is supposed to avoid bias due to the size of datasets (for instance, melanoma datasets were significantly smaller that the others).</p></sec><sec id="s3_5"><title>Selection of treatment dependent correlations</title><p>A correlation difference test was used to select correlations that vary between responsive and non-responsive tumor. It is based on the Steiger Test (r.test in R package &#x0201c;psych&#x0201d; [<xref rid="R48" ref-type="bibr">48</xref>]). This method is applied for a &#x0201c;one-sided test of different correlation, between responsive and non-responsive, in 4 datasets&#x0201d; in the flow chart of Figure <xref ref-type="fig" rid="F7">7A</xref>, for producing Figure <xref ref-type="fig" rid="F7">7B, 7C</xref>.</p></sec><sec id="s3_6"><title>Two modes distribution separation</title><p>The package &#x0201c;mixtools&#x0201d; [<xref rid="R49" ref-type="bibr">49</xref>], within R environment [<xref rid="R46" ref-type="bibr">46</xref>], was used to separate reproducible correlation distribution (Figure <xref ref-type="fig" rid="F6">6A</xref>) in two parts, applying an EM algorithm on a double Gaussian model. We imposed that each Gaussian mode represents at least 20% of the whole set of reproducible correlations</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY MATERIALS, FIGURES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-06-11894-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1329" position="anchor"/></supplementary-material></sec></body><back><ack><p>We would like to thank D. Enot for his advices in statistics.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Conflicts of Interest</bold></p><p>The authors declare no conflict of interest.</p></fn><fn fn-type="supported-by"><p><bold>Grant Support</bold></p><p>GK is supported by the Ligue contre le Cancer (&#x000e9;quipe labellis&#x000e9;e); Agence National de la Recherche (ANR) &#x02013; Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc&#x000e9;rop&#x000f4;le Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche M&#x000e9;dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Noske</surname><given-names>A</given-names></name><name><surname>Roller</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>BM</given-names></name><name><surname>Komor</surname><given-names>M</given-names></name><name><surname>Budczies</surname><given-names>J</given-names></name><name><surname>Darb-Esfahani</surname><given-names>S</given-names></name><name><surname>Kronenwett</surname><given-names>R</given-names></name><name><surname>Hanusch</surname><given-names>C</given-names></name><name><surname>von Torne</surname><given-names>C</given-names></name><name><surname>Weichert</surname><given-names>W</given-names></name><name><surname>Engels</surname><given-names>K</given-names></name><name><surname>Solbach</surname><given-names>C</given-names></name><name><surname>Schrader</surname><given-names>I</given-names></name><name><surname>Dietel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">19917869</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group><name><surname>Anitei</surname><given-names>MG</given-names></name><name><surname>Zeitoun</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Marliot</surname><given-names>F</given-names></name><name><surname>Haicheur</surname><given-names>N</given-names></name><name><surname>Todosi</surname><given-names>AM</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Lagorce</surname><given-names>C</given-names></name><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Ferariu</surname><given-names>D</given-names></name><name><surname>Danciu</surname><given-names>M</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Scripcariu</surname><given-names>V</given-names></name><name><surname>Chevallier</surname><given-names>JM</given-names></name><name><surname>Zinzindohoue</surname><given-names>F</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic and predictive values of the immunoscore in patients with rectal cancer</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>1891</fpage><lpage>1899</lpage><pub-id pub-id-type="pmid">24691640</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Thurin</surname><given-names>M</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>BA</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name></person-group><article-title>The immune score as a new possible approach for the classification of cancer</article-title><source>J Transl Med</source><year>2012</year><volume>10</volume><fpage>1</fpage><pub-id pub-id-type="pmid">22214470</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group><name><surname>Vasaturo</surname><given-names>A</given-names></name><name><surname>Verweij</surname><given-names>D</given-names></name><name><surname>Heinzerling</surname><given-names>L</given-names></name><name><surname>de Vries</surname><given-names>J</given-names></name><name><surname>Blokx</surname><given-names>W</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients</article-title><source>J Transl Med</source><year>2015</year><volume>13</volume><fpage>2080</fpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group><name><surname>Goc</surname><given-names>J</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Hammond</surname><given-names>SA</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>MC</given-names></name></person-group><article-title>Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e28976</fpage><pub-id pub-id-type="pmid">25083325</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group><name><surname>Salmon</surname><given-names>H</given-names></name><name><surname>Franciszkiewicz</surname><given-names>K</given-names></name><name><surname>Damotte</surname><given-names>D</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>MC</given-names></name><name><surname>Validire</surname><given-names>P</given-names></name><name><surname>Trautmann</surname><given-names>A</given-names></name><name><surname>Mami-Chouaib</surname><given-names>F</given-names></name><name><surname>Donnadieu</surname><given-names>E</given-names></name></person-group><article-title>Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>899</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">22293174</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Lagorce-Pages</surname><given-names>C</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Wind</surname><given-names>P</given-names></name><name><surname>Zinzindohoue</surname><given-names>F</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Cugnenc</surname><given-names>PH</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="pmid">17008531</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Meatchi</surname><given-names>T</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><article-title>Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">21245428</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Molidor</surname><given-names>R</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Damotte</surname><given-names>D</given-names></name><name><surname>Meatchi</surname><given-names>T</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Cugnenc</surname><given-names>PH</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><article-title>Effector memory T cells, early metastasis, and survival in colorectal cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>2654</fpage><lpage>2666</lpage><pub-id pub-id-type="pmid">16371631</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><article-title>The immune contexture in human tumours: impact on clinical outcome</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">22419253</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Waldner</surname><given-names>M</given-names></name><name><surname>Obenauf</surname><given-names>AC</given-names></name><name><surname>Angell</surname><given-names>H</given-names></name><name><surname>Fredriksen</surname><given-names>T</given-names></name><name><surname>Lafontaine</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Speicher</surname><given-names>MR</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>782</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">24138885</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name></person-group><article-title>Neutralizing tumor-promoting chronic inflammation: a magic bullet?</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">23329041</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group><name><surname>Finn</surname><given-names>OJ</given-names></name></person-group><article-title>Cancer immunology</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2704</fpage><lpage>2715</lpage><pub-id pub-id-type="pmid">18565863</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group><name><surname>Remark</surname><given-names>R</given-names></name><name><surname>Alifano</surname><given-names>M</given-names></name><name><surname>Cremer</surname><given-names>I</given-names></name><name><surname>Lupo</surname><given-names>A</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>MC</given-names></name><name><surname>Riquet</surname><given-names>M</given-names></name><name><surname>Crozet</surname><given-names>L</given-names></name><name><surname>Ouakrim</surname><given-names>H</given-names></name><name><surname>Goc</surname><given-names>J</given-names></name><name><surname>Cazes</surname><given-names>A</given-names></name><name><surname>Flejou</surname><given-names>JF</given-names></name><name><surname>Gibault</surname><given-names>L</given-names></name><name><surname>Verkarre</surname><given-names>V</given-names></name><name><surname>Regnard</surname><given-names>JF</given-names></name><name><surname>Pages</surname><given-names>ON</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><fpage>4079</fpage><lpage>4091</lpage><pub-id pub-id-type="pmid">23785047</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group><name><surname>Badoual</surname><given-names>C</given-names></name><name><surname>Hans</surname><given-names>S</given-names></name><name><surname>Merillon</surname><given-names>N</given-names></name><name><surname>Van Ryswick</surname><given-names>C</given-names></name><name><surname>Ravel</surname><given-names>P</given-names></name><name><surname>Benhamouda</surname><given-names>N</given-names></name><name><surname>Levionnois</surname><given-names>E</given-names></name><name><surname>Nizard</surname><given-names>M</given-names></name><name><surname>Si-Mohamed</surname><given-names>A</given-names></name><name><surname>Besnier</surname><given-names>N</given-names></name><name><surname>Gey</surname><given-names>A</given-names></name><name><surname>Rotem-Yehudar</surname><given-names>R</given-names></name><name><surname>Pere</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Guerin</surname><given-names>CL</given-names></name><name><surname>Chauvat</surname><given-names>A</given-names></name><etal/></person-group><article-title>PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">23135914</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name></person-group><article-title>RNA-Seq: a revolutionary tool for transcriptomics</article-title><source>Nat Rev Genet</source><year>2009</year><volume>10</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19015660</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group><name><surname>Angelova</surname><given-names>M</given-names></name><name><surname>Charoentong</surname><given-names>P</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><name><surname>Fischer</surname><given-names>ML</given-names></name><name><surname>Snajder</surname><given-names>R</given-names></name><name><surname>Krogsdam</surname><given-names>AM</given-names></name><name><surname>Waldner</surname><given-names>MJ</given-names></name><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name></person-group><article-title>Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><fpage>64</fpage><pub-id pub-id-type="pmid">25853550</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group><name><surname>Stoll</surname><given-names>G</given-names></name><name><surname>Enot</surname><given-names>D</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>e27884</fpage><pub-id pub-id-type="pmid">24790795</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>SS</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Brunet</surname><given-names>JP</given-names></name><name><surname>Wagner</surname><given-names>SN</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases</article-title><source>Mol Cancer Res</source><year>2008</year><volume>6</volume><fpage>760</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">18505921</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group><name><surname>Harlin</surname><given-names>H</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Peterson</surname><given-names>AC</given-names></name><name><surname>Zha</surname><given-names>Y</given-names></name><name><surname>Tretiakova</surname><given-names>M</given-names></name><name><surname>Slingluff</surname><given-names>C</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><article-title>Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>3077</fpage><lpage>3085</lpage><pub-id pub-id-type="pmid">19293190</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group><name><surname>Bogunovic</surname><given-names>D</given-names></name><name><surname>O'Neill</surname><given-names>DW</given-names></name><name><surname>Belitskaya-Levy</surname><given-names>I</given-names></name><name><surname>Vacic</surname><given-names>V</given-names></name><name><surname>Yu</surname><given-names>YL</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Darvishian</surname><given-names>F</given-names></name><name><surname>Berman</surname><given-names>R</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Pavlick</surname><given-names>AC</given-names></name><name><surname>Lonardi</surname><given-names>S</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Osman</surname><given-names>I</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>20429</fpage><lpage>20434</lpage><pub-id pub-id-type="pmid">19915147</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group><name><surname>Riker</surname><given-names>AI</given-names></name><name><surname>Enkemann</surname><given-names>SA</given-names></name><name><surname>Fodstad</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Howell</surname><given-names>P</given-names></name><name><surname>Metge</surname><given-names>B</given-names></name><name><surname>Samant</surname><given-names>RS</given-names></name><name><surname>Shevde</surname><given-names>LA</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Eschrich</surname><given-names>S</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Ju</surname><given-names>J</given-names></name><name><surname>Matta</surname><given-names>J</given-names></name></person-group><article-title>The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis</article-title><source>BMC Med Genomics</source><year>2008</year><volume>1</volume><fpage>13</fpage><pub-id pub-id-type="pmid">18442402</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group><name><surname>Talantov</surname><given-names>D</given-names></name><name><surname>Mazumder</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>JX</given-names></name><name><surname>Briggs</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Backus</surname><given-names>J</given-names></name><name><surname>Atkins</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Novel genes associated with malignant melanoma but not benign melanocytic lesions</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>7234</fpage><lpage>7242</lpage><pub-id pub-id-type="pmid">16243793</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group><name><surname>Freeman</surname><given-names>TJ</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Roland</surname><given-names>JT</given-names></name><name><surname>Means</surname><given-names>AL</given-names></name><name><surname>Eschrich</surname><given-names>SA</given-names></name><name><surname>Yeatman</surname><given-names>TJ</given-names></name><name><surname>Deane</surname><given-names>NG and</given-names></name><name><surname>Beauchamp</surname><given-names>RD</given-names></name></person-group><article-title>Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><fpage>562</fpage><lpage>571</lpage><comment>e562</comment><pub-id pub-id-type="pmid">22115830</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Deane</surname><given-names>NG</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Merchant</surname><given-names>NB</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>JC</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>CE</given-names></name><name><surname>Eschrich</surname><given-names>S</given-names></name><name><surname>Kis</surname><given-names>C</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Heslin</surname><given-names>MJ</given-names></name><name><surname>Coffey</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>958</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">19914252</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group><name><surname>Sanz-Pamplona</surname><given-names>R</given-names></name><name><surname>Cordero</surname><given-names>D</given-names></name><name><surname>Berenguer</surname><given-names>A</given-names></name><name><surname>Lejbkowicz</surname><given-names>F</given-names></name><name><surname>Rennert</surname><given-names>H</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Biondo</surname><given-names>S</given-names></name><name><surname>Sanjuan</surname><given-names>X</given-names></name><name><surname>Pujana</surname><given-names>MA</given-names></name><name><surname>Rozek</surname><given-names>L</given-names></name><name><surname>Giordano</surname><given-names>TJ</given-names></name><name><surname>Ben-Izhak</surname><given-names>O</given-names></name><name><surname>Cohen</surname><given-names>HI</given-names></name><name><surname>Trougouboff</surname><given-names>P</given-names></name><name><surname>Bejhar</surname><given-names>J</given-names></name><name><surname>Sova</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gene expression differences between colon and rectum tumors</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>7303</fpage><lpage>7312</lpage><pub-id pub-id-type="pmid">21976543</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group><name><surname>Schmit</surname><given-names>SL</given-names></name><name><surname>Gollub</surname><given-names>J</given-names></name><name><surname>Shapero</surname><given-names>MH</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Rennert</surname><given-names>HS</given-names></name><name><surname>Finn</surname><given-names>A</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Gruber</surname><given-names>SB</given-names></name></person-group><article-title>MicroRNA polymorphisms and risk of colorectal cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2015</year><volume>24</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">25342389</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group><name><surname>Vilar</surname><given-names>E</given-names></name><name><surname>Bartnik</surname><given-names>CM</given-names></name><name><surname>Stenzel</surname><given-names>SL</given-names></name><name><surname>Raskin</surname><given-names>L</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Mukherjee</surname><given-names>B</given-names></name><name><surname>Iniesta</surname><given-names>MD</given-names></name><name><surname>Morgan</surname><given-names>MA</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Gruber</surname><given-names>SB</given-names></name></person-group><article-title>MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>2632</fpage><lpage>2642</lpage><pub-id pub-id-type="pmid">21300766</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group><name><surname>Bonnefoi</surname><given-names>H</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Mauriac</surname><given-names>L</given-names></name><name><surname>Fumoleau</surname><given-names>P</given-names></name><name><surname>Brain</surname><given-names>E</given-names></name><name><surname>Petit</surname><given-names>T</given-names></name><name><surname>Rouanet</surname><given-names>P</given-names></name><name><surname>Jassem</surname><given-names>J</given-names></name><name><surname>Blot</surname><given-names>E</given-names></name><name><surname>Zaman</surname><given-names>K</given-names></name><name><surname>Cufer</surname><given-names>T</given-names></name><name><surname>Lortholary</surname><given-names>A</given-names></name><name><surname>Lidbrink</surname><given-names>E</given-names></name><name><surname>Andre</surname><given-names>S</given-names></name><name><surname>Litiere</surname><given-names>S</given-names></name><etal/></person-group><article-title>TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>527</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">21570352</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group><name><surname>Hatzis</surname><given-names>C</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Booser</surname><given-names>DJ</given-names></name><name><surname>Esserman</surname><given-names>L</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Vidaurre</surname><given-names>T</given-names></name><name><surname>Holmes</surname><given-names>F</given-names></name><name><surname>Souchon</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Cotrina</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>H</given-names></name><name><surname>Hubbard</surname><given-names>R</given-names></name><name><surname>Chacon</surname><given-names>JI</given-names></name><name><surname>Ferrer-Lozano</surname><given-names>J</given-names></name><etal/></person-group><article-title>A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>1873</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">21558518</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group><name><surname>Tabchy</surname><given-names>A</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Vidaurre</surname><given-names>T</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Barajas-Figueroa</surname><given-names>LJ</given-names></name><name><surname>Souchon</surname><given-names>E</given-names></name><name><surname>Coutant</surname><given-names>C</given-names></name><name><surname>Doimi</surname><given-names>FD</given-names></name><name><surname>Ibrahim</surname><given-names>NK</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>5351</fpage><lpage>5361</lpage><pub-id pub-id-type="pmid">20829329</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group><name><surname>Korde</surname><given-names>LA</given-names></name><name><surname>Lusa</surname><given-names>L</given-names></name><name><surname>McShane</surname><given-names>L</given-names></name><name><surname>Lebowitz</surname><given-names>PF</given-names></name><name><surname>Lukes</surname><given-names>L</given-names></name><name><surname>Camphausen</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Hunter</surname><given-names>K</given-names></name><name><surname>Zujewski</surname><given-names>JA</given-names></name></person-group><article-title>Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2010</year><volume>119</volume><fpage>685</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">20012355</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group><name><surname>Shedden</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>JM</given-names></name><name><surname>Enkemann</surname><given-names>SA</given-names></name><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Yeatman</surname><given-names>TJ</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Eschrich</surname><given-names>S</given-names></name><name><surname>Jurisica</surname><given-names>I</given-names></name><name><surname>Giordano</surname><given-names>TJ</given-names></name><name><surname>Misek</surname><given-names>DE</given-names></name><name><surname>Chang</surname><given-names>AC</given-names></name><name><surname>Zhu</surname><given-names>CQ</given-names></name><name><surname>Strumpf</surname><given-names>D</given-names></name><name><surname>Hanash</surname><given-names>S</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>822</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">18641660</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Son</surname><given-names>DS</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jo</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>HY</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Shim</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>7397</fpage><lpage>7404</lpage><pub-id pub-id-type="pmid">19010856</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group><name><surname>Okayama</surname><given-names>H</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Shiraishi</surname><given-names>K</given-names></name><name><surname>Iwakawa</surname><given-names>R</given-names></name><name><surname>Furuta</surname><given-names>K</given-names></name><name><surname>Tsuta</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Kumamoto</surname><given-names>K</given-names></name><name><surname>Takenoshita</surname><given-names>S</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>100</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">22080568</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>R</given-names></name><name><surname>Nakata</surname><given-names>A</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Nagasaki</surname><given-names>M</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Imoto</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>A</given-names></name><name><surname>Ueno</surname><given-names>K</given-names></name><name><surname>Hatanaka</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name><name><surname>Yokota</surname><given-names>J</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e43923</fpage><pub-id pub-id-type="pmid">23028479</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group><name><surname>Raponi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>JM</given-names></name><name><surname>Macdonald</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Moskaluk</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name></person-group><article-title>Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>7466</fpage><lpage>7472</lpage><pub-id pub-id-type="pmid">16885343</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group><name><surname>Fischer</surname><given-names>CL</given-names></name><name><surname>Blanchette</surname><given-names>DR</given-names></name><name><surname>Brogden</surname><given-names>KA</given-names></name><name><surname>Dawson</surname><given-names>DV</given-names></name><name><surname>Drake</surname><given-names>DR</given-names></name><name><surname>Hill</surname><given-names>JR</given-names></name><name><surname>Wertz</surname><given-names>PW</given-names></name></person-group><article-title>The roles of cutaneous lipids in host defense</article-title><source>Biochim Biophys Acta</source><year>2014</year><volume>1841</volume><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">23994607</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group><name><surname>Pitson</surname><given-names>SM</given-names></name></person-group><article-title>Regulation of sphingosine kinase and sphingolipid signaling</article-title><source>Trends Biochem Sci</source><year>2011</year><volume>36</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">20870412</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2015</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>5</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">25559415</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Angell</surname><given-names>HK</given-names></name><name><surname>Bedognetti</surname><given-names>D</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name></person-group><article-title>The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>11</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">23890060</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group><name><surname>Sanger</surname><given-names>N</given-names></name><name><surname>Ruckhaberle</surname><given-names>E</given-names></name><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Engels</surname><given-names>K</given-names></name><name><surname>Heinrich</surname><given-names>T</given-names></name><name><surname>Fehm</surname><given-names>T</given-names></name><name><surname>Graf</surname><given-names>A</given-names></name><name><surname>Holtrich</surname><given-names>U</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Karn</surname><given-names>T</given-names></name></person-group><article-title>Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer</article-title><source>Mol Oncol</source><year>2015</year><volume>9</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">25131496</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group><name><surname>Morad</surname><given-names>SA</given-names></name><name><surname>Levin</surname><given-names>JC</given-names></name><name><surname>Tan</surname><given-names>SF</given-names></name><name><surname>Fox</surname><given-names>TE</given-names></name><name><surname>Feith</surname><given-names>DJ</given-names></name><name><surname>Cabot</surname><given-names>MC</given-names></name></person-group><article-title>Novel off-target effect of tamoxifen-inhibition of acid ceramidase activity in cancer cells</article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1831</volume><fpage>1657</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">23939396</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group><name><surname>Milde-Langosch</surname><given-names>K</given-names></name><name><surname>Karn</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>zu Eulenburg</surname><given-names>C</given-names></name><name><surname>Oliveira-Ferrer</surname><given-names>L</given-names></name><name><surname>Wirtz</surname><given-names>RM</given-names></name><name><surname>Schumacher</surname><given-names>U</given-names></name><name><surname>Witzel</surname><given-names>I</given-names></name><name><surname>Schutze</surname><given-names>D</given-names></name><name><surname>Muller</surname><given-names>V</given-names></name></person-group><article-title>Prognostic relevance of glycosylation-associated genes in breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2014</year><volume>145</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">24737166</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Szallasi</surname><given-names>Z</given-names></name><name><surname>Eklund</surname><given-names>AC</given-names></name></person-group><article-title>Jetset: selecting the optimal microarray probe set to represent a gene</article-title><source>BMC Bioinformatics</source><year>2011</year><volume>12</volume><fpage>474</fpage><pub-id pub-id-type="pmid">22172014</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="book"><collab>R Development Core Team</collab><year>2008</year><source>R: A Language and Environment for Statistical Computing</source><publisher-loc>Vienna, Austria</publisher-loc></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group><name><surname>Morey</surname><given-names>JS</given-names></name><name><surname>Ryan</surname><given-names>JC</given-names></name><name><surname>Van Dolah</surname><given-names>FM</given-names></name></person-group><article-title>Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR</article-title><source>Biol Proced Online</source><year>2006</year><volume>8</volume><fpage>175</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">17242735</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group><name><surname>Revelle</surname><given-names>W</given-names></name></person-group><year>2015</year><article-title>psych: Procedures for Psychological, Psychometric, and Personality Research</article-title><source>Evanston, Illinois</source></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group><name><surname>Benaglia</surname><given-names>T</given-names></name><name><surname>Chauveau</surname><given-names>D</given-names></name><name><surname>Hunter</surname><given-names>DR</given-names></name><name><surname>Young</surname><given-names>D</given-names></name></person-group><article-title>mixtools: An R Package for Analyzing Finite Mixture Models</article-title><source>Journal of Statistical Software</source><year>2009</year><volume>32</volume><fpage>1</fpage><lpage>29</lpage></element-citation></ref></ref-list></back></article>